keyword
MENU ▼
Read by QxMD icon Read
search

Soonmyung paik

keyword
https://www.readbyqxmd.com/read/27864694/the-effect-on-surgical-complications-of-bevacizumab-added-to-neoadjuvant-chemotherapy-for-breast-cancer-nrg-oncology-nsabp-protocol-b-40
#1
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Christine K Zoon, Kelley M Kidwell, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NRG Oncology/NSABP trial B-40 tested the impact of adding bevacizumab (bev) to neoadjuvant chemotherapy for operable breast cancer. Secondary endpoints included rates of surgical complications after surgery in patients who did or did not receive bev. METHODS: A total of 1206 women with HER2-negative operable breast cancer were randomly assigned to receive one of three different docetaxel-plus-anthracycline-based regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively...
November 18, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27812689/association-of-polymorphisms-in-fcgr2a-and-fcgr3a-with-degree-of-trastuzumab-benefit-in-the-adjuvant-treatment-of-erbb2-her2-positive-breast-cancer-analysis-of-the-nsabp-b-31-trial
#2
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Jong-Hyeon Jeong, Joseph P Costantino, Norman Wolmark, Soonmyung Paik, Kay L Pogue-Geile
Importance: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. Objective: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer...
November 3, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27270348/clinical-outcome-from-oxaliplatin-treatment-in-stage-ii-iii-colon-cancer-according-to-intrinsic-subtypes-secondary-analysis-of-nsabp-c-07-nrg-oncology-randomized-clinical-trial
#3
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim, Nicole L Johnson, Corey Lipchik, Carmen J Allegra, Nicholas J Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer has been shown to provide significant but modest absolute benefit for disease-free survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for markers that predict oxaliplatin benefit. OBJECTIVE: To test our hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy...
September 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27217450/prognostic-impact-of-the-combination-of-recurrence-score-and-quantitative-estrogen-receptor-expression-esr1-on-predicting-late-distant-recurrence-risk-in-estrogen-receptor-positive-breast-cancer-after-5-years-of-tamoxifen-results-from-nrg-oncology-national
#4
Norman Wolmark, Eleftherios P Mamounas, Frederick L Baehner, Steven M Butler, Gong Tang, Farid Jamshidian, Amy P Sing, Steven Shak, Soonmyung Paik
PURPOSE: We determined the utility of the 21-Gene Recurrence Score (RS) in predicting late (> 5 years) distant recurrence (LDR) in stage I and II breast cancer within high and low-ESR1-expressing groups. PATIENTS AND METHODS: RS was assessed in chemotherapy/tamoxifen-treated, estrogen receptor (ER) -positive, node-positive National Surgical Adjuvant Breast and Bowel Project B-28 patients and tamoxifen-treated, ER-positive, node-negative B-14 patients. The association of the RS with risk of distant recurrence (DR) 0 to 5 years and those at risk > 5 years was assessed...
July 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27196768/egfr-mediated-reactivation-of-mapk-signaling-induces-acquired-resistance-to-gsk2118436-in-braf-v600e-mutant-nsclc-cell-lines
#5
Sung-Moo Kim, Hwan Kim, Kang Won Jang, Min Hwan Kim, Jinyoung Sohn, Mi Ran Yun, Han Na Kang, Chan Woo Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
Although treatment of BRAF V600E-mutant non-small cell lung cancer (NSCLC(V600E)) with GSK2118436 has shown an encouraging efficacy, most patients develop resistance. To investigate the mechanisms of acquired resistance to GSK2118436 in NSCLC(V600E), we established GSK2118436-resistant (GSR) cells by exposing MV522 NSCLC(V600E) to increasing GSK2118436 concentrations. GSR cells displayed activated EGFR-RAS-CRAF signaling with upregulated EGFR ligands and sustained activation of ERK1/2, but not MEK1/2, in the presence of GSK2118436...
July 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/26992220/genomic-profiling-of-lung-adenocarcinoma-patients-reveals-therapeutic-targets-and-confers-clinical-benefit-when-standard-molecular-testing-is-negative
#6
Sun Min Lim, Eun Young Kim, Hye Ryun Kim, Siraj M Ali, Joel R Greenbowe, Hyo Sup Shim, Hyun Chang, Seungtaek Lim, Soonmyung Paik, Byoung Chul Cho
BACKGROUND: Identification of clinically relevant oncogenic drivers in advanced cancer is critical in selecting appropriate targeted therapy. Using next-generation sequencing (NGS)-based clinical cancer gene assay, we performed comprehensive genomic profiling (CGP) of advanced cases of lung adenocarcinoma. METHODS: Formalin-fixed paraffin-embedded tumors from 51 lung adenocarcinoma patients whose tumors previously tested negative for EGFR/KRAS/ALK by conventional methods were collected, and CGP was performed via hybridization capture of 4,557 exons from 287 cancer-related genes and 47 introns from 19 genes frequently rearranged in cancer...
April 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/26789870/cdx2-as-a-prognostic-biomarker-in-stage-ii-and-stage-iii-colon-cancer
#7
Piero Dalerba, Debashis Sahoo, Soonmyung Paik, Xiangqian Guo, Greg Yothers, Nan Song, Nate Wilcox-Fogel, Erna Forgó, Pradeep S Rajendran, Stephen P Miranda, Shigeo Hisamori, Jacqueline Hutchison, Tomer Kalisky, Dalong Qian, Norman Wolmark, George A Fisher, Matt van de Rijn, Michael F Clarke
Background The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice. Methods We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation across gene-expression arrays and then ranked candidate genes according to the availability of clinical-grade diagnostic assays...
January 21, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26633601/prognostic-tests-for-estrogen-receptor-positive-breast-cancer-need-for-global-consideration-and-further-evolution
#8
EDITORIAL
Jee Ye Kim, Seung-Il Kim, Soonmyung Paik
No abstract text is available yet for this article.
February 2016: JAMA Oncology
https://www.readbyqxmd.com/read/26462025/phase-ii-clinical-and-exploratory-biomarker-study-of-dacomitinib-in-recurrent-and-or-metastatic-esophageal-squamous-cell-carcinoma
#9
MULTICENTER STUDY
Hyo Song Kim, Sung-Moo Kim, Hyunki Kim, Kyoung-Ho Pyo, Jong-Mu Sun, Myung-Ju Ahn, Keunchil Park, Bhumsuk Keam, Nak-Jung Kwon, Hwan Jung Yun, Hoon-Gu Kim, Ik-Joo Chung, Jong Seok Lee, Kyung Hee Lee, Dae Joon Kim, Chang-Geol Lee, Jin Hur, Hyunsoo Chung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Hye Ryun Kim, Yong Wha Moon, Yong Chan Lee, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
The purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, whose diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, were treated with dacomitinib 45 mg/day. The primary endpoint was objective response rate by RECISTv 1.1. Predictive biomarker analyses included the characterization of somatic mutations and gene expression using the Ion Torrent AmpliSeq Cancer Hotspot Panel and Nanostring nCounter, and investigation of their relationship with clinical outcomes...
December 29, 2015: Oncotarget
https://www.readbyqxmd.com/read/26412349/prospective-validation-of-a-21-gene-expression-assay-in-breast-cancer
#10
RANDOMIZED CONTROLLED TRIAL
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Edith A Perez, John A Olson, JoAnne Zujewski, Tracy Lively, Sunil S Badve, Thomas J Saphner, Lynne I Wagner, Timothy J Whelan, Matthew J Ellis, Soonmyung Paik, William C Wood, Peter Ravdin, Maccon M Keane, Henry L Gomez Moreno, Pavan S Reddy, Timothy F Goggins, Ingrid A Mayer, Adam M Brufsky, Deborah L Toppmeyer, Virginia G Kaklamani, James N Atkins, Jeffrey L Berenberg, George W Sledge
BACKGROUND: Prior studies with the use of a prospective-retrospective design including archival tumor samples have shown that gene-expression assays provide clinically useful prognostic information. However, a prospectively conducted study in a uniformly treated population provides the highest level of evidence supporting the clinical validity and usefulness of a biomarker. METHODS: We performed a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1...
November 19, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/26272770/neoadjuvant-plus-adjuvant-bevacizumab-in-early-breast-cancer-nsabp-b-40-nrg-oncology-secondary-outcomes-of-a-phase-3-randomised-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Harry D Bear, Gong Tang, Priya Rastogi, Charles E Geyer, Qing Liu, André Robidoux, Luis Baez-Diaz, Adam M Brufsky, Rita S Mehta, Louis Fehrenbacher, James A Young, Francis M Senecal, Rakesh Gaur, Richard G Margolese, Paul T Adams, Howard M Gross, Joseph P Costantino, Soonmyung Paik, Sandra M Swain, Eleftherios P Mamounas, Norman Wolmark
BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adjuvant bevacizumab to neoadjuvant chemotherapy regimens would also improve outcomes. As reported previously, addition of neoadjuvant bevacizumab increased the proportion of patients achieving a pathological complete response, which was the primary endpoint...
September 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26256959/cancer-cell-line-panels-empower-genomics-based-discovery-of-precision-cancer-medicine
#12
REVIEW
Hyun Seok Kim, Yeo-Jin Sung, Soonmyung Paik
Since the first human cancer cell line, HeLa, was established in the early 1950s, there has been a steady increase in the number and tumor type of available cancer cell line models. Cancer cell lines have made significant contributions to the development of various chemotherapeutic agents. Recent advances in multi-omics technologies have facilitated detailed characterizations of the genomic, transcriptomic, proteomic, and epigenomic profiles of these cancer cell lines. An increasing number of studies employ the power of a cancer cell line panel to provide predictive biomarkers for targeted and cytotoxic agents, including those that are already used in clinical practice...
September 2015: Yonsei Medical Journal
https://www.readbyqxmd.com/read/26208525/antitumor-activity-and-acquired-resistance-mechanism-of-dovitinib-tki258-in-ret-rearranged-lung-adenocarcinoma
#13
Chan Woo Kang, Kang Won Jang, Jinyoung Sohn, Sung-Moo Kim, Kyoung-Ho Pyo, Hwan Kim, Mi Ran Yun, Han Na Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Soonmyung Paik, Dae Joon Kim, Joo Hang Kim, Byoung Chul Cho
RET rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in RET-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in RET-rearranged LADC. Using structural modeling and in vitro analysis, we demonstrated that dovitinib induced cell-cycle arrest at G0-G1 phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in RET-rearranged LC-2/ad cells...
October 2015: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/25753441/reply-to-e-a-rakha-et-al
#14
COMMENT
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Kimberly H Allison, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons, Wedad Hanna, Robert B Jenkins, Pamela B Mangu, Soonmyung Paik, Edith A Perez, Michael F Press, Patricia A Spears, Gail H Vance, Giuseppe Viale, Mitch Dowsett, Lisa M McShane, Daniel F Hayes
No abstract text is available yet for this article.
April 10, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/25575444/a-polygenic-risk-score-for-breast-cancer-in-women-receiving-tamoxifen-or-raloxifene-on-nsabp-p-1-and-p-2
#15
Celine M Vachon, Daniel J Schaid, James N Ingle, D Lawrence Wickerham, Michiaki Kubo, Taisei Mushiroda, Matthew P Goetz, Erin E Carlson, Soonmyung Paik, Norman Wolmark, Yusuke Nakamura, Liewei Wang, Richard Weinshilboum, Fergus J Couch
Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case-control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs...
January 2015: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/25559813/intrinsic-subtypes-pik3ca-mutation-and-the-degree-of-benefit-from-adjuvant-trastuzumab-in-the-nsabp-b-31-trial
#16
Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim, Nicole L Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive value of these two biomarkers in the adjuvant setting using archived tumor blocks from National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31...
April 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/25424851/phase-ii-clinical-and-exploratory-biomarker-study-of-dacomitinib-in-patients-with-recurrent-and-or-metastatic-squamous-cell-carcinoma-of-head-and-neck
#17
MULTICENTER STUDY
Han Sang Kim, Hyeong Ju Kwon, Inkyung Jung, Mi Ran Yun, Myung-Ju Ahn, Byung Woog Kang, Jong-Mu Sun, Sung Bae Kim, Dok-Hyun Yoon, Keon Uk Park, Se-Hoon Lee, Yoon Woo Koh, Se Hun Kim, Eun Chang Choi, Dong Hoe Koo, Jin Hee Sohn, Bomi Kim, Nak-Jung Kwon, Hwan Jung Yun, Min Goo Lee, Ji Hyun Lee, Tae-Min Kim, Hye Ryun Kim, Joo Hang Kim, Soonmyung Paik, Byoung Chul Cho
PURPOSE: The goals of this study were to investigate the clinical activity, safety, and biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and HER4, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). EXPERIMENTAL DESIGN: Patients were eligible if the diseases were not amenable to curative treatment and had progressed on platinum-based chemotherapy, and were treated with dacomitinib 45 mg/day...
February 1, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/25423180/nanomaterials-for-theranostics-recent-advances-and-future-challenges
#18
REVIEW
Eun-Kyung Lim, Taekhoon Kim, Soonmyung Paik, Seungjoo Haam, Yong-Min Huh, Kwangyeol Lee
No abstract text is available yet for this article.
January 14, 2015: Chemical Reviews
https://www.readbyqxmd.com/read/24529560/pathological-complete-response-and-long-term-clinical-benefit-in-breast-cancer-the-ctneobc-pooled-analysis
#19
REVIEW
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M Swain, Tatiana Prowell, Sibylle Loibl, D Lawrence Wickerham, Jan Bogaerts, Jose Baselga, Charles Perou, Gideon Blumenthal, Jens Blohmer, Eleftherios P Mamounas, Jonas Bergh, Vladimir Semiglazov, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, Wolfgang Eiermann, Gunter von Minckwitz
BACKGROUND: Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS). We had four key objectives: to establish the association between pathological complete response and EFS and OS, to establish the definition of pathological complete response that correlates best with long-term outcome, to identify the breast cancer subtypes in which pathological complete response is best correlated with long-term outcome, and to assess whether an increase in frequency of pathological complete response between treatment groups predicts improved EFS and OS...
July 12, 2014: Lancet
https://www.readbyqxmd.com/read/24262440/predicting-degree-of-benefit-from-adjuvant-trastuzumab-in-nsabp-trial-b-31
#20
RANDOMIZED CONTROLLED TRIAL
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G Gavin, Debora Fumagalli, Lynn C Goldstein, Nour Sneige, Eike Burandt, Yusuke Taniyama, Olga L Bohn, Ahwon Lee, Seung-Il Kim, Megan L Reilly, Matthew Y Remillard, Nicole L Blackmon, Seong-Rim Kim, Zachary D Horne, Priya Rastogi, Louis Fehrenbacher, Edward H Romond, Sandra M Swain, Eleftherios P Mamounas, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. METHODS: Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay...
December 4, 2013: Journal of the National Cancer Institute
keyword
keyword
80336
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"